AVROBIO Inc
NASDAQ:TECX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AVROBIO Inc
NASDAQ:TECX
|
US |
|
Valiant Holding AG
SIX:VATN
|
CH |
|
B
|
Boston Scientific Corp
DUS:BSX
|
US |
|
E
|
EOG Resources Inc
XMUN:EO5
|
US |
|
Midea Real Estate Holding Ltd
F:MR9
|
CN |
|
Iberdrola SA
MAD:IBE
|
ES |
|
Swisscom AG
SIX:SCMN
|
CH |
|
Globalstar Inc
F:P8S0
|
US |
|
Dufry AG
LSE:0QK3
|
CH |
|
R
|
Ryohin Keikaku Co Ltd
OTC:RYKKF
|
JP |
|
Spotify Technology SA
NYSE:SPOT
|
LU |
|
ZTO Express (Cayman) Inc
F:ZTOB
|
CN |
|
A
|
Abbvie Inc
XETRA:4AB
|
US |
AVROBIO Inc
AVROBIO Inc. is a biotechnology company that develops gene therapies for rare inherited diseases. Its core idea is to take a patient’s own blood-forming stem cells, add a working copy of a faulty gene in the lab, and put the corrected cells back into the body. The goal is to treat the root cause of the disease rather than manage symptoms with lifelong medicines. Because it is a drug developer, AVROBIO does not sell a broad catalog of products to everyday consumers. Its work is aimed at patients with serious single-gene disorders, and any future sales would likely flow through hospitals, specialty treatment centers, and healthcare payers after regulatory approval. Like many biotech companies at this stage, it has mainly depended on financing, research partnerships, and other drug-development funding rather than product sales. What makes AVROBIO’s model different is the treatment style it is pursuing. Instead of making a drug that patients take repeatedly, it is trying to create one-time or infrequent gene therapies based on a patient’s own cells. That makes the science more complex and expensive than standard medicines, but it also gives the company a chance to target diseases where existing treatments are limited or only manage symptoms.
AVROBIO Inc. is a biotechnology company that develops gene therapies for rare inherited diseases. Its core idea is to take a patient’s own blood-forming stem cells, add a working copy of a faulty gene in the lab, and put the corrected cells back into the body. The goal is to treat the root cause of the disease rather than manage symptoms with lifelong medicines.
Because it is a drug developer, AVROBIO does not sell a broad catalog of products to everyday consumers. Its work is aimed at patients with serious single-gene disorders, and any future sales would likely flow through hospitals, specialty treatment centers, and healthcare payers after regulatory approval. Like many biotech companies at this stage, it has mainly depended on financing, research partnerships, and other drug-development funding rather than product sales.
What makes AVROBIO’s model different is the treatment style it is pursuing. Instead of making a drug that patients take repeatedly, it is trying to create one-time or infrequent gene therapies based on a patient’s own cells. That makes the science more complex and expensive than standard medicines, but it also gives the company a chance to target diseases where existing treatments are limited or only manage symptoms.
